Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
Investing.com -- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) stock surged 103% following the announcement that SERB Pharmaceuticals will acquire the company in an all-cash transaction valued at approximately $412 million.
Under the terms of the agreement, SERB will commence a tender offer to purchase all outstanding shares of Y-mAbs for $8.60 per share, representing a premium of approximately 105% to Y-mAbs’ closing price on August 4, 2025.
The acquisition will add Y-mAbs’ lead commercial asset DANYELZA (naxitamab-gqgk), an FDA-approved treatment for relapsed or refractory high-risk neuroblastoma, to SERB’s portfolio of medicines for rare diseases. DANYELZA is the first FDA-approved treatment for this rare and aggressive pediatric cancer.
The transaction was unanimously approved by Y-mAbs’ Board of Directors after a review of strategic alternatives to maximize stockholder value. The process included discussions with numerous potential buyers and consideration of additional capital sources to support pipeline development.
"This transaction is a testament to our team’s hard work in building a strong foundation as a commercial organization with a differentiated, FDA-approved product in DANYELZA," said Michael Rossi, President and CEO of Y-mAbs. "By combining our expertise and resources with SERB’s specialty commercial capabilities, we can extend our shared commitment of improving the lives of even more patients and families on a global scale."
SERB CEO Vanessa Wolfeler stated that the acquisition will allow the company to continue generating data for DANYELZA, expand partnerships to additional oncology centers, and have a positive impact on more neuroblastoma patients.
Y-mAbs stockholders holding approximately 16% of outstanding shares have agreed to tender their shares. The transaction is expected to close by the fourth quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.